This discovery emphasizes the biological heterogeneity within HER2-negative breast cancer, as HER2-low tumors show sensitivity to next-generation anti-HER2 antibody-drug conjugates such as trastuzumab deruxtecan (11). The gene discussed is ERBB2; the disease is breast cancer.